Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Truax

Showing results (231-240 of 248) with videos related to

Pageof 25
Sort By:
Nature Immunology|March 14, 2017
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Nature Immunology|October 19, 2017
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-ChainsEdgars Jecs, Eric J Miller, Robert J Wilson, et al.
Cell Reports|August 18, 2021
Hypoxic preconditioning protects against ischemic kidney injury through the IDO1/kynurenine pathwayRafael Torosyan, Shengping Huang, Prashant V Bommi, et al.
ACS Medicinal Chemistry Letters|June 18, 2014
Discovery of tetrahydroisoquinoline-based CXCR4 antagonistsValarie M Truax, Huanyu Zhao, Brooke M Katzman, et al.
ACS Medicinal Chemistry Letters|May 26, 2018
Discovery of <i>N</i>-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like PropertiesYesim A Tahirovic, Valarie M Truax, Robert J Wilson, et al.
ACS Medicinal Chemistry Letters|January 20, 2018
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 AntagonistsRobert J Wilson, Edgars Jecs, Eric J Miller, et al.
Journal of Medicinal Chemistry|July 28, 2018
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME PropertiesHuy H Nguyen, Michelle B Kim, Robert J Wilson, et al.
Nature Communications|December 19, 2025
Synchronous mid-Holocene marine and terrestrial deglaciation in the Ross Sea, AntarcticaRebecca L Parker, Christina R Riesselman, Olivia J Truax, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)Karen E Bullock, William P Petros, Islam Younis, et al.
Pageof 25

Showing results (231-240 of 248) with videos related to

Sort By:
Pageof 25
Nature Immunology|March 14, 2017
NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
Nature Immunology|October 19, 2017
Corrigendum: NLRP12 attenuates colon inflammation by maintaining colonic microbial diversity and promoting protective commensal bacterial growthLiang Chen, Justin E Wilson, Mark J Koenigsknecht, et al.
ACS Medicinal Chemistry Letters|February 20, 2018
Synthesis of Novel Tetrahydroisoquinoline CXCR4 Antagonists with Rigidified Side-ChainsEdgars Jecs, Eric J Miller, Robert J Wilson, et al.
Cell Reports|August 18, 2021
Hypoxic preconditioning protects against ischemic kidney injury through the IDO1/kynurenine pathwayRafael Torosyan, Shengping Huang, Prashant V Bommi, et al.
ACS Medicinal Chemistry Letters|June 18, 2014
Discovery of tetrahydroisoquinoline-based CXCR4 antagonistsValarie M Truax, Huanyu Zhao, Brooke M Katzman, et al.
ACS Medicinal Chemistry Letters|May 26, 2018
Discovery of <i>N</i>-Alkyl Piperazine Side Chain Based CXCR4 Antagonists with Improved Drug-like PropertiesYesim A Tahirovic, Valarie M Truax, Robert J Wilson, et al.
ACS Medicinal Chemistry Letters|January 20, 2018
Synthesis and SAR of 1,2,3,4-Tetrahydroisoquinoline-Based CXCR4 AntagonistsRobert J Wilson, Edgars Jecs, Eric J Miller, et al.
Journal of Medicinal Chemistry|July 28, 2018
Design, Synthesis, and Pharmacological Evaluation of Second-Generation Tetrahydroisoquinoline-Based CXCR4 Antagonists with Favorable ADME PropertiesHuy H Nguyen, Michelle B Kim, Robert J Wilson, et al.
Nature Communications|December 19, 2025
Synchronous mid-Holocene marine and terrestrial deglaciation in the Ross Sea, AntarcticaRebecca L Parker, Christina R Riesselman, Olivia J Truax, et al.
Cancer Chemotherapy and Pharmacology|November 17, 2010
A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE)Karen E Bullock, William P Petros, Islam Younis, et al.
Pageof 25